HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for hard-to-treat breast cancer
Disease control Recruiting nowThis study tests a combination of two drugs (Sac-TMT and Tagitanlimab) in 35 people with a specific type of advanced breast cancer that is hormone receptor-positive, HER2-negative, and PD-L1-positive. Participants must have already been treated with a CDK4/6 inhibitor. The goal i…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Vaccine-Drug combo targets Hard-to-Treat breast cancer
Disease control Recruiting nowThis early study tests whether combining a special immune-boosting vaccine (DC1) with the drug elacestrant is safe and doable for people with a common type of advanced breast cancer (HR+ HER2-). About 18 participants will receive the treatment for 8 weeks. The goal is to see if t…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Blood test may cut unnecessary scans for breast cancer patients
Knowledge-focused Recruiting nowThis study tests whether a blood test called DiviTum TKa can help doctors decide to order fewer scans and other tests for women with HR+ HER2- metastatic breast cancer. The trial will enroll 55 women starting a common first-line treatment. Doctors will fill out care plans before …
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC